Ondine Biomedical Inc said its shares started trading on London’s AIM market today.
The Canadian company has pioneered a new non-antibiotic antimicrobial technology called photodisinfection which rapidly destroys pathogens - including SARS-CoV-2 - without causing resistance.
It made its debut in London with a market value of £104mln, City AM reported.
Ondine raised around £23mln prior to the listing.
Shares were trading at 58p midmorning.